202 related articles for article (PubMed ID: 28566436)
1. Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G
Chatterjee S; Huang EH; Christie I; Burns TF
Mol Cancer Ther; 2017 Aug; 16(8):1658-1668. PubMed ID: 28566436
[TBL] [Abstract][Full Text] [Related]
2. Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in
Chatterjee S; Huang EH; Christie I; Kurland BF; Burns TF
Mol Cancer Ther; 2017 May; 16(5):793-804. PubMed ID: 28167505
[TBL] [Abstract][Full Text] [Related]
3. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA
Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
Ramalingam S; Goss G; Rosell R; Schmid-Bindert G; Zaric B; Andric Z; Bondarenko I; Komov D; Ceric T; Khuri F; Samarzija M; Felip E; Ciuleanu T; Hirsh V; Wehler T; Spicer J; Salgia R; Shapiro G; Sheldon E; Teofilovici F; Vukovic V; Fennell D
Ann Oncol; 2015 Aug; 26(8):1741-8. PubMed ID: 25997818
[TBL] [Abstract][Full Text] [Related]
5. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
Kurihara E; Shien K; Torigoe H; Takeda T; Takahashi Y; Ogoshi Y; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Okazaki M; Shien T; Tomida S; Toyooka S
Anticancer Res; 2019 Apr; 39(4):1767-1775. PubMed ID: 30952716
[TBL] [Abstract][Full Text] [Related]
6. Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.
Wu X; Marmarelis ME; Hodi FS
PLoS One; 2013; 8(2):e56134. PubMed ID: 23418523
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of Cdc25C by pp90Rsk contributes to a G2 cell cycle arrest in Xenopus cycling egg extracts.
Chun J; Chau AS; Maingat FG; Edmonds SD; Ostergaard HL; Shibuya EK
Cell Cycle; 2005 Jan; 4(1):148-54. PubMed ID: 15539959
[TBL] [Abstract][Full Text] [Related]
8. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
[TBL] [Abstract][Full Text] [Related]
9. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.
Cercek A; Shia J; Gollub M; Chou JF; Capanu M; Raasch P; Reidy-Lagunes D; Proia DA; Vakiani E; Solit DB; Saltz LB
Clin Colorectal Cancer; 2014 Dec; 13(4):207-12. PubMed ID: 25444464
[TBL] [Abstract][Full Text] [Related]
10. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
11. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
Proia DA; Sang J; He S; Smith DL; Sequeira M; Zhang C; Liu Y; Ye S; Zhou D; Blackman RK; Foley KP; Koya K; Wada Y
Invest New Drugs; 2012 Dec; 30(6):2201-9. PubMed ID: 22227828
[TBL] [Abstract][Full Text] [Related]
12. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
[TBL] [Abstract][Full Text] [Related]
13. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
[TBL] [Abstract][Full Text] [Related]
14. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
Sang J; Acquaviva J; Friedland JC; Smith DL; Sequeira M; Zhang C; Jiang Q; Xue L; Lovly CM; Jimenez JP; Shaw AT; Doebele RC; He S; Bates RC; Camidge DR; Morris SW; El-Hariry I; Proia DA
Cancer Discov; 2013 Apr; 3(4):430-43. PubMed ID: 23533265
[TBL] [Abstract][Full Text] [Related]
15. Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.
Al Nakouzi N; Cotteret S; Commo F; Gaudin C; Rajpar S; Dessen P; Vielh P; Fizazi K; Chauchereau A
Oncotarget; 2014 Feb; 5(3):667-78. PubMed ID: 24525428
[TBL] [Abstract][Full Text] [Related]
16. Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer.
Yoon S; Yang H; Ryu HM; Lee E; Jo Y; Seo S; Kim D; Lee CH; Kim W; Jung KH; Park SR; Choi EK; Kim SW; Park KS; Lee DH
Cancer Res Treat; 2022 Jul; 54(3):767-781. PubMed ID: 34607394
[TBL] [Abstract][Full Text] [Related]
17. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.
Wang Y; Liu H; Diao L; Potter A; Zhang J; Qiao Y; Wang J; Proia DA; Tailor R; Komaki R; Lin SH
Clin Cancer Res; 2016 Dec; 22(23):5876-5886. PubMed ID: 27354472
[TBL] [Abstract][Full Text] [Related]
19. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer.
Liu H; Lu J; Hua Y; Zhang P; Liang Z; Ruan L; Lian C; Shi H; Chen K; Tu Z
Cell Death Dis; 2015 Jan; 6(1):e1595. PubMed ID: 25590805
[TBL] [Abstract][Full Text] [Related]
20. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]